Baar MP, Brandt RMC, Putavet DA, et al
doi: 10.4103/2230-8210.176346
Laboratory studies further underscore its potential for improving gut health, spinal cord injury recovery, chronic pain management, and cognitive function, suggesting possible future clinical applications
My question: given my MS stability but significant metabolic risk factors (obesity, pre-diabetes, cholesterol, thyroid), do you think a GLP-1 agonist (such as tirzepatide or semaglutide) would be a reasonable option for me
Although it was hoped that, given lower manufacturing costs, the oral version would be priced lower than the injectable, currently that is not the case
One practical tip for people choosing a commercial product is to favor transparent brands that publish human data and thirdparty testing